ArticleThe EMBO journal2000
MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis.
Article in The EMBO journal, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 79 citations in OpenAlex.
- Bioinformatics analysis proposes a possible role for long noncoding RNA MIR17HG in retinoblastoma.Cancer reports (Hoboken, N.J.) · 2024Article
- Optimized spirooxindole-pyrazole hybrids targeting the p53-MDM2 interplay induce apoptosis and synergize with doxorubicin in A549 cells.Scientific reports · 2023Article
- Synthesis and Biological Evaluation of NovelMolecules (Basel, Switzerland) · 2023Article
- Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation.Frontiers in chemistry · 2021Article
- S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity.PloS one · 2020Article
- DNA replication in progenitor cells and epithelial regeneration after lung injury requires the oncoprotein MDM2.JCI insight · 2019Article
- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.Cold Spring Harbor perspectives in medicine · 2017Review
- Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Journal of medicinal chemistry · 2015Review
- Reduced P53 Staining in Actinic Keratosis is Associated with Squamous Cell Carcinoma: A Preliminary Study.Indian journal of dermatology · 2013Article
- Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Review
- A novel regulation of VEGF expression by HIF-1α and STAT3 in HDM2 transfected prostate cancer cells.Journal of cellular and molecular medicine · 2012Article
- Article
- Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.Molecular and cellular biology · 2010Article
- Expression of COUP-TF-interacting protein 2 (CTIP2) in human atopic dermatitis and allergic contact dermatitis skin.Experimental dermatology · 2009Article
- Recent advances in validating MDM2 as a cancer target.Anti-cancer agents in medicinal chemistry · 2009Review
- Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.Annual review of pharmacology and toxicology · 2009Review
- Regulation of Notch1 gene expression by p53 in epithelial cells.Molecular and cellular biology · 2007Article
- Review
- Keratinocyte apoptosis in epidermal development and disease.The Journal of investigative dermatology · 2006Review
- Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway.Oncogene · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The MDM2 oncogene is overexpressed in 5-10% of human tumours. Its major physiological role is to inhibit the tumour suppressor p53. However, MDM2 has p53-independent effects on differentiation and does not predispose to tumorigenesis when it is expressed in the granular layer of the epidermis. These unexpected properties of MDM2 could be tissue specific or could depend on the differentiation state of the cells. Strikingly, we found that MDM2 has p53-dependent effects on differentiation, proliferation and apoptosis when it is expressed in the less differentiated basal layer cells. MDM2 inhibits UV induction of p53, the cell cycle inhibitor p21(WAF1/CIP1) and apoptosis ('sunburn cells'). Importantly, MDM2 increases papilloma formation induced by chemical carcinogenesis and predisposes to the appearance of premalignant lesions and squamous cell carcinomas. p53 has a natural role in the protection against UV damage in the basal layer of the epidermis. Our results show that MDM2 predisposes to tumorigenesis when expressed at an early stage of differentiation, and provide a mouse model of MDM2 tumorigenesis relevant to p53's tumour suppressor functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.